Valuation: ASKA Pharmaceutical Holdings Co.,Ltd.

Market Cap 65.37B 402M 352M 325M 303M 571M 38.02B 581M 3.9B 1.51B 18.76B 1.51B 1.48B P/E 2027 *
14x
P/E 2028 * 11.8x
Enterprise Value 65.37B 402M 352M 325M 303M 571M 38.02B 581M 3.9B 1.51B 18.76B 1.51B 1.48B EV / Sales 2027 *
0.89x
EV / Sales 2028 * 0.87x
Free-Float
61.83%
Yield 2027 *
2.82%
Yield 2028 * 3.04%
06-25 Declaration of Voting Results by Asuka Pharmaceutical CI
05-27 Dalton Investment strongly oppose conditional activation of countermeasures announced by ASKA Pharmaceutical Holdings on May 25 RE
05-25 Aska pharmaceutical - plan to put to shareholders proposal on countermeasures against potential large-scale share purchase by Dalton and related parties RE
05-11 Asuka Pharmaceutical Opposes Nippon Active Value Fund Plc?s Shareholder Proposal for Board Changes at 2026 Annual Meeting CI
05-11 ASKA Pharmaceutical Holdings Co.,Ltd. Announces Change in Dividend Policy CI
05-11 ASKA Pharmaceutical Holdings Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
05-11 ASKA Pharmaceutical Holdings Co.,Ltd. Proposes Year-End Dividend for Fiscal Year Ended March 31, 2026, Payable on June 25, 2026; Provides Dividend Guidance for End of Second Quarter of Fiscal Year Ending March 31, 2027 CI
05-11 ASKA Pharmaceutical Holdings Co.,Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2027 CI
05-11 ASKA Pharmaceutical Holdings Co.,Ltd. Announces Retirement of Kazuhiro Chiku as Audit & Supervisory Board Member, Effective June 24, 2026 CI
04-14 FTS AMBROSE HOLDINGS, INC. announced that it has received funding from ASKA Pharmaceutical Holdings Co.,Ltd. CI
03-24 Insilico Medicine And ASKA Pharmaceutical Enter Strategic Research Collaboration For Women's Health CI
03-24 Aska Pharmaceutical Holdings Co Ltd - Insilico Medicine and Aska Pharmaceutical expand partnership to discover novel targets for women's health RE
03-23 ASKA Targets 85 Billion Yen Revenue Under New Mid-term Plan MT
1 day+1.32%
1 week+1.05%
Current month-21.43%
1 month-21.43%
3 months-2.83%
6 months+11.21%
Current year+12.95%
1 week 2,149
Extreme 2149
2,329
1 month 2,149
Extreme 2149
2,898
Current year 2,038
Extreme 2038
3,045
1 year 1,920
Extreme 1920
3,045
3 years 1,396
Extreme 1396
3,045
5 years 919
Extreme 919
3,045
10 years 776
Extreme 776
3,045
Manager TitleAgeSince
Chief Executive Officer - -
President 42 24/06/2025
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 74 24/06/2025
Director/Board Member 67 01/04/2021
Director/Board Member 42 01/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
+1.32%+1.05%-5.23%+59.20% 398M
-2.48%+8.34%+53.87%+155.75% 1,097B
-1.76%+6.23%+66.27%+53.44% 622B
-1.05%+7.19%+35.57%+86.77% 449B
-1.62%+6.34%+29.51%+24.01% 334B
-1.38%+6.09%+37.91%+25.49% 294B
+0.30%+5.24%+31.61%+42.02% 286B
-0.10%+4.88%-28.09%-41.02% 213B
+0.44%+4.35%+29.69%+63.10% 195B
+0.01%+1.03%+13.95%+63.93% 157B
Average -0.50%+6.08%+26.51%+53.27% 364.71B
Weighted average by Cap. -1.14%+8.72%+40.66%+77.92%

Financials

2027 *2028 *
Net sales 73.12B 450M 394M 363M 339M 639M 42.54B 650M 4.36B 1.69B 20.99B 1.69B 1.65B 74.96B 461M 404M 373M 348M 655M 43.6B 667M 4.47B 1.74B 21.52B 1.73B 1.69B
Net income 4.67B 28.72M 25.14M 23.21M 21.65M 40.79M 2.72B 41.52M 278M 108M 1.34B 108M 106M 5.52B 33.98M 29.75M 27.46M 25.61M 48.26M 3.21B 49.12M 329M 128M 1.59B 128M 125M
Net Debt - -
Logo ASKA Pharmaceutical Holdings Co.,Ltd.
ASKA Pharmaceutical Holdings Co Ltd is a Japan-based company primarily engaged in the pharmaceutical business. The Company has three business segments. The Pharmaceutical Business segment primarily manufactures and sells prescription pharmaceuticals. The Animal Health Business segment primarily manufactures and sells veterinary medicines, feed additives, and other products. The Overseas Business segment primarily manufactures and sells prescription pharmaceuticals overseas. The Company also engages in clinical testing and medical equipment businesses.
Employees
1,611
Date Price Change Volume
30/06/26 ¥2,302.00 +1.32% 85,800
29/06/26 ¥2,272.00 +4.46% 153,400
26/06/26 ¥2,175.00 -2.77% 84,800
25/06/26 ¥2,237.00 -1.50% 109,800
24/06/26 ¥2,271.00 -0.22% 127,100
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
2,302.00JPY
Average target price
2,400.00JPY
Spread / Average Target
+4.26%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4886 Stock